Hengrui Medicine (600276.SH): SHR-3201 Injection Receives Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3201 Injection, and will soon initiate clinical trials. The applied indication: Alzheimer's disease.